Welcome to our dedicated page for Climb Bio SEC filings (Ticker: CLYM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Climb Bio, Inc. (Nasdaq: CLYM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Climb Bio is a clinical-stage biotechnology company developing monoclonal antibody therapeutics for immune-mediated and B-cell mediated diseases, and its filings offer structured insight into how it reports material events, governance changes, and financial updates.
Recent Form 8-K filings describe key developments such as quarterly financial results, publication of clinical data for budoprutug in primary membranous nephropathy, and new preclinical data for CLYM116 in IgA nephropathy. Other 8-Ks detail the appointment of senior executives, including the Chief Financial Officer, and related equity awards granted under the company’s 2025 Inducement Plan, as well as amendments to increase the share reserve under that plan. These documents also confirm that Climb Bio’s common stock trades on The Nasdaq Global Market under the symbol CLYM.
Through Stock Titan, users can review Climb Bio’s SEC filings alongside AI-powered summaries that highlight the main points of each document. This includes explanations of how the company characterizes the therapeutic potential and clinical development of budoprutug and CLYM116 in its disclosures, and how it describes risks and forward-looking statements associated with its programs. The filings page is also a resource for tracking regulatory communications around investor events, data releases, and other reportable events.
By using this page, investors and researchers can quickly locate Climb Bio’s 8-Ks and other SEC reports and rely on AI-generated overviews to understand the significance of each filing without reading every line of the underlying documents.
Climb Bio, Inc. reported new preclinical results for its monoclonal antibody CLYM116, which targets APRIL and is being developed for IgA nephropathy. In a completed nonhuman primate study, CLYM116 showed deeper IgA reduction and a longer half-life compared with sibeprenlimab, a first-generation anti-APRIL antibody, suggesting a potential for less frequent dosing. Additional in vivo mouse studies showed enhanced APRIL elimination and antibody recycling versus sibeprenlimab.
The company plans, subject to regulatory clearance, to start a Phase 1 trial of CLYM116 in healthy volunteers in
Schedule 13G: Pontifax-related entities report collective beneficial ownership of 5,206,380 shares of Climb Bio common stock, representing 7.7% of the class. The holdings are held in two limited partnerships (Pontifax (Israel) VI L.P. and Pontifax (Cayman) VI L.P.) controlled through Pontifax VI G.P. L.P. and Pontifax Management 4 G.P. (2015) Ltd., with Tomer Kariv and Ran Nussbaum identified as managing members. Reported power is shared voting and dispositive power over the full position; no sole voting or sole dispositive power is claimed.